An indirect comparison of HbA_1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method

References

• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2015 38 1 140 149 25538310
   PubMed Web of Science ®Google Scholar
• Tanzeum (albiglutide) [package insert] Wilmington, DE GlaxoSmith-Kline LLC 2015
   Google Scholar
• Bydureon (exenatide) [package insert] Wilmington, DE AstraZeneca Pharmaceuticals LP 2015
   Google Scholar
• Trulicity (dulaglutide) [package insert] Indianapolis, IN Eli Lilly and Company 2015
   Google Scholar
• Trujillo JM Nuffer W Ellis SL GLP-1 receptor agonists: a review of head-to-head clinical studies Ther Adv Endocrinol Metab 2015 6 1 19 28 25678953
   PubMed Web of Science ®Google Scholar
• Bucher HC Guyatt GH Griffith LE Walter SD The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 1997 50 6 683 691 9250266
   PubMed Web of Science ®Google Scholar
• Pratley RE Nauck MA Barnett AH Once weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study Lancet Diabetes Endocrinol 2014 2 4 289 297 24703047
   PubMed Web of Science ®Google Scholar
• Buse JB Nauck M Forst T Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 2013 381 117 124 23141817
   PubMed Web of Science ®Google Scholar
• Reusch J Stewart MW Perkins CM Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin Diabetes Obes Metab 2014 16 1257 1264 25155146
   PubMed Web of Science ®Google Scholar
• Nauck MA Stewart MW Perkins C Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetologia 2016 59 2 266 274 26577795
   PubMed Web of Science ®Google Scholar
• Ahren B Johnson SL Stewart M HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin Diabetes Care 2014 37 8 2141 2148 24898304
   PubMed Web of Science ®Google Scholar
• Weissman P Carr M Ye J HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea Diabetologia 2014 57 2475 2484 25208756
   PubMed Web of Science ®Google Scholar
• Home PD Shamanna P Stewart M Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5 Diabetes Obes Metab 2015 17 179 187 25406730
   PubMed Web of Science ®Google Scholar
• Rosenstock J Fonseca VA Gross JL Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro Diabetes Care 2014 37 8 2317 2325 24898300
   PubMed Web of Science ®Google Scholar
• Leiter LA Carr MC Stewart M Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study Diabetes Care 2014 37 10 2723 2730 25048383
   PubMed Web of Science ®Google Scholar
• Drucker DJ Buse JB Taylor K Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 2008 372 9645 1240 1250 18782641
   PubMed Web of Science ®Google Scholar
• Diamant M Van GL Stranks S Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial Lancet 2010 375 9733 2234 2243 20609969
   PubMed Web of Science ®Google Scholar
• Bergenstal RM Wysham C Macconell L Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 2010 376 9739 431 439 20580422
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Cuddihy RM Hanefeld M Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Diabetes Care 2012 35 2 252 258 22210563
   PubMed Web of Science ®Google Scholar
• Blevins T Pullman J Malloy J DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes J Clin Endocrinol Metab 2011 96 5 1301 1310 21307137
   PubMed Web of Science ®Google Scholar
• Inagaki N Atsumi Y Oura T Saito H Imaoka T Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study Clin Ther 2012 34 9 1892 1908 22884767
   PubMed Web of Science ®Google Scholar
• Ji L Onishi Y Ahn CW Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus J Diabetes Investig 2013 4 1 53 61
   PubMed Web of Science ®Google Scholar
• Guidance for Industry Non-Inferiority Clinical Trials Silver Spring, MD US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research 2010
   Google Scholar
• Salanti G Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool Res Synth Methods 2012 3 2 80 97 26062083
   PubMed Web of Science ®Google Scholar
• Zinman B Gerich J Buse JB Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) Diabetes Care 2009 32 1224 1230 19289857
   PubMed Web of Science ®Google Scholar
• Nauck M Frid A Hermansen K Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study Diabetes Care 2009 32 1 84 90 18931095
   PubMed Web of Science ®Google Scholar
• Scott DA Boye KS Timlin L Clark JF Best JH A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo Diabetes Obes Metab 2013 15 213 223 22958381
   PubMed Web of Science ®Google Scholar
• Dias S Welton NJ Sutton AJ Caldwell DM Lu G Ades AE homepage on the Internet NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials 2011 [updated April 2012]; Available from: http://www.nicedsu.org.uk Accessed January 18, 2016
   Google Scholar